2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6011 Comparison of ATG‑based and PTCy‑based graft-versus-host disease (GVHD) prophylaxis in older patients undergoing haploidentical hematopoietic stem cell transplantation: A study from the acute leukemia working party (ALWP) of the European society for blood and marrow transplantation (EBMT)

Yuqian Sun, MD, Rui MA2, Maud Ngoya3, Raynier Devillier, PhD4, Anna Maria Raiola, MD5, Fabio Ciceri, MD6, Stefania Bramanti7, Renato Fanin8, Johanna Tischer9, Simona Sica, MD, PhD10, Maija Itälä-Remes11, Francis Ayuk12, Giovanni Grillo, MD13, Johannes Schetelig14, Gesine Bug, MD15, Lucia Lopez Corral, MD, PhD16, Gwendolyn Van Gorkom, MD, PhD17, Mohamad Mohty, MD, PhD18, Norbert Claude Gorin, MD, PhD19, Alexandros Spyridonidis20, Francesco Saraceni, MD21, Frederic Baron22, Jaime Sanz, MD, PhD23, Arnon Nagler I, MD24, Xiaojun Huang, MD, PhD25, Eolia Brissot, MD, PhD26
1 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, BEIJING, China
2 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, BEIJING, China
3 EBMT Paris Study Unit, Hôpital Saint-Antoine, Paris, France
4 Programme de Transplantation & Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France
5 AOM-IRCCS Ospedale Policlinico San Martino. Genova. UO Ematologia e Terapie Cellulari, Genova, Italy
6 IRCCS San Raffaele Hospital Scientific Institute, Milan, Italy
7 Istituto Clinico Humanitas, Milan, Italy
8 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
9 Klinikum Grosshadern, University of Munich, Munich, Germany
10 Universita Cattolica S. Cuore, Rome, Italy
11 Turku University Hospital, Turku, Finland
12 University Hospital Eppendorf, Hamburg, Germany
13 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
14 Universitaetsklinikum Dresden, Dresden, Germany
15 University Hospital Frankfurt – Goethe University, Frankfurt am Main, Germany
16 Hospital Clinico de Salamanca, Salamanca, Spain
17 University Hospital Maastricht, Maastricht, Netherlands
18 Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
19 Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
20 Bone Marrow Transplantation Unit and Institute of Cell Therapy, University of Patras, Rio, Greece
21 Ematologia, Trapianto e Terapia Cellulare, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy
22 University of Liege, Liege, Belgium
23 Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, Valencia, Spain
24 Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
25 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, BEIJING, China
26 Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France

Background Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is widely used, yet the optimal graft-versus-host disease (GVHD) prophylaxis in the older population remains unclear. Anti-thymocyte globulin (ATG)-based and post-transplant cyclophosphamide (PTCy)-based regimens are the two main platforms. Both have shown efficacy, but direct comparisons in older patients (≥60 years) remain limited. We therefore compared ATG- and PTCy-based prophylaxis in a retrospective, registry-based study.

Methods Patients aged ≥60 years with AML who underwent first haplo-HSCT between 2013 and 2023 were identified from the EBMT registry. Patients receiving both ATG and PTCy, or neither, were excluded. The primary endpoint was overall survival (OS). Secondary endpoints included engraftment, non-relapse mortality (NRM), relapse, grade II-IV acute GVHD (aGVHD), extensive chronic GVHD (cGVHD), leukemia-free survival (LFS), and GVHD-free/relapse-free survival (GRFS). Kaplan–Meier estimation was used for OS and LFS, and cumulative-incidence methods with competing risks were applied for relapse, NRM, engraftment, and GVHD. Multivariable analysis, adjusting for potential confounding factors, was performed using Cox proportional hazards regression models for the main transplantation outcomes.

Results A total of 2,006 patients were included (ATG, n=120; PTCy, n=1,886). The ATG group had earlier transplant years (median 2018 vs. 2020, p<0.0001), younger patients (64.4 vs. 65.8 years, p<0.0001), and a longer diagnosis-to-transplant interval (7.7 vs. 5.7 months, p=0.0004). ATG recipients were more often female (49.2% vs. 37.3%, p=0.009) and received more bone marrow grafts (33.3% vs. 22.1%, p=0.004). Cytogenetic risk (data available for 1,720 patients, 85.7%) was adverse in 22.4% vs. 24.9%, intermediate in 75.5% vs. 72.3%, and favorable in 2.0% vs. 2.8% (ATG vs. PTCy). MRD data were available for 798 patients (39.8%), with comparable rates of MRD negativity between groups (66.7% vs 61.2%, p=0.47). With a median follow-up of 3.2 years, the 2-year OS was 47.4% (95% CI 37.7-56.4) with ATG vs. 52.7% (95% CI 50.3-55.1) with PTCy (p=0.53), and the 2-year LFS was 45.0% (95% CI 35.5-54.1) vs. 48.8% (95% CI 46.4-51.2) (p=0.49). Neutrophil recovery by day 30 was higher in the ATG group (89.8% vs. 87.5%, p<0.0001), rising to 94.9% vs. 91.7% by day 60. Platelet recovery by day 30 was also better with ATG (76.9% vs. 58.5%, p<0.0001), reaching 86.5% vs. 80.4% by day 60. ATG was associated with numerically lower risk of grade II-IV aGVHD (ATG vs. PTCy, HR 0.64, 95% CI 0.40–1.04, p=0.07) in multivariate analysis, with no significant differences observed for grade III–IV aGVHD (ATG vs. PTCy, HR 0.85, 95% CI 0.45-1.63, p=0.63), overall cGVHD (ATG vs. PTCy, HR 0.85, 95% CI 0.52-1.37, p=0.50), or extensive cGVHD (ATG vs. PTCy, HR 1.28, 95% CI 0.49-3.35, p=0.61). The cumulative incidence of relapse was comparable (17.2% vs. 22.7%, p=0.18), whereas NRM was numerically higher with ATG but did not differ significantly in multivariable analysis (37.8% vs. 28.4%, p=0.24). The 2-year GRFS was comparable (36.5% vs. 40.2%, p=0.78). Among 1,022 documented deaths (64 in ATG, 958 in PTCy), relapse was the leading cause, accounting for 25.8% of deaths in ATG and 38.4% in the PTCy group, followed by infection (24.2% vs. 19.6%), and other treatment-related causes (16.1% vs. 8.5%). In the overall cohort, older age (HR 1.06 per 2-year increment, p=0.002) and KPS <90 (KPS <90 vs. ≥90, HR 1.52, p<0.001) were independently associated with worse OS, whereas more recent transplant year was protective (HR 0.85 per 5-year increment, p=0.02). GVHD prophylaxis with ATG or PTCy was not significantly associated with OS (ATG vs. PTCy, HR 1.03, 95% CI 0.76-1.39, p=0.86).

Conclusions In this large registry-based cohort of older patients undergoing haplo-HSCT, no significant differences were observed between ATG- and PTCy-based GVHD prophylaxis for OS, LFS, GVHD, relapse, NRM, and GRFS after multivariable adjustment. ATG showed faster neutrophil and platelet recovery, though this finding should be interpreted with caution given differences in graft source and other baseline characteristics. Due to the retrospective design, several limitations must be acknowledged, including marked sample size imbalance, potential residual confounding, and limited MRD data availability. Furthermore, differences in causes of death should be interpreted cautiously owing to the small size of ATG group.
Yuqian Sun, MD: No relevant conflicts of interest to declare.